{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,3]],"date-time":"2026-11-03T22:31:24Z","timestamp":1793745084991,"version":"4.6.1"},"reference-count":54,"publisher":"American Society of Hematology","issue":"14","content-domain":{"domain":["ashpublications.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2026,7,28]]},"abstract":"<jats:sec>\n                    <jats:title>Abstract<\/jats:title>\n                    <jats:p>Graft-versus-host disease (GVHD) is a major risk factor for transplant-associated thrombotic microangiopathy (TA-TMA), and the 2 conditions often co-occur; therefore, we evaluated the biomarkers of endothelial injury to clarify their relationship. Our prospective Microangiopathy, Endothelial Damage in Adults Undergoing Stem Cell Transplantation cohort study of 368 adult (aged \u226518 years) patients measured biomarkers before and after their first allogeneic hematopoietic cell transplantation (HCT). We found that posttransplant cyclophosphamide significantly reduced acute GVHD incidence but had no impact on the reduction of TA-TMA incidence. Severe TA-TMA occurred in the absence of acute GVHD but also occurred more frequently with higher grades of acute GVHD. Pretransplant serum creatinine and detectable placental growth factor were associated with post-HCT TA-TMA. In sex-stratified multivariable models, a 1 mg\/dL increase in pretransplant creatinine conferred a \u223c40-fold higher TA-TMA risk in females vs approximately fivefold in males. Both landmark and association analyses identified day +28 creatinine and suppression of tumorigenicity 2 (ST2) as significant TA-TMA risk factors. Our study phenotyped TA-TMA and GVHD concurrently, and we show that ST2, previously linked to GVHD treatment response and nonrelapse mortality (NRM), also predicted TA-TMA. Day +28 levels of ST2, soluble FLT-1, and epidermal growth factor were associated with NRM and overall survival (OS), whereas baseline or day +28 soluble C5b-9 was not associated with TA-TMA. Post hoc analyses of Endothelial Activation and Stress Index composite score at day +28 after HCT found significant associations with severe TA-TMA, acute GVHD, NRM, and OS. Overall, our data highlight distinct risk factors and biomarker profiles for TA-TMA and GVHD and also identify differences between adults and reported biomarkers of TA-TMA in children.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1182\/bloodadvances.2026019747","type":"journal-article","created":{"date-parts":[[2026,6,3]],"date-time":"2026-06-03T19:53:41Z","timestamp":1780516421000},"page":"5076-5086","update-policy":"https:\/\/doi.org\/10.1182\/blood.2019cm0000","source":"Crossref","is-referenced-by-count":3,"title":["TA-TMA and GVHD are distinct consequences of endothelial injury: a MIDAS consortium study"],"prefix":"10.1182","volume":"10","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-3835-8855","authenticated-orcid":false,"given":"Theresa","family":"Hahn","sequence":"first","affiliation":[{"name":"1Roswell Park Comprehensive Cancer Center, Buffalo, NY"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qiuhong","family":"Zhao","sequence":"additional","affiliation":[{"name":"2Division of Hematology, The Ohio State University, Columbus, OH"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elizabeth Greer","family":"Miller","sequence":"additional","affiliation":[{"name":"2Division of Hematology, The Ohio State University, Columbus, OH"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Patrick","family":"Elder","sequence":"additional","affiliation":[{"name":"2Division of Hematology, The Ohio State University, Columbus, OH"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lucille","family":"Langenberg","sequence":"additional","affiliation":[{"name":"3Cincinnati Children\u2019s Medical Center, Cincinnati, OH"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nathan","family":"Luebbering","sequence":"additional","affiliation":[{"name":"3Cincinnati Children\u2019s Medical Center, Cincinnati, OH"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sheyar","family":"Abdullah","sequence":"additional","affiliation":[{"name":"3Cincinnati Children\u2019s Medical Center, Cincinnati, OH"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lotus","family":"Neidemire-Colley","sequence":"additional","affiliation":[{"name":"2Division of Hematology, The Ohio State University, Columbus, OH"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5054-9419","authenticated-orcid":false,"given":"Shernan G.","family":"Holtan","sequence":"additional","affiliation":[{"name":"1Roswell Park Comprehensive Cancer Center, Buffalo, NY"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8977-6910","authenticated-orcid":false,"given":"Spero","family":"Cataland","sequence":"additional","affiliation":[{"name":"2Division of Hematology, The Ohio State University, Columbus, OH"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Parvathi","family":"Ranganathan","sequence":"additional","affiliation":[{"name":"2Division of Hematology, The Ohio State University, Columbus, OH"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stella M.","family":"Davies","sequence":"additional","affiliation":[{"name":"3Cincinnati Children\u2019s Medical Center, Cincinnati, OH"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0194-7338","authenticated-orcid":false,"given":"Nelli","family":"Bejanyan","sequence":"additional","affiliation":[{"name":"4Moffitt Comprehensive Cancer Center, Tampa, FL"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8635-3880","authenticated-orcid":false,"given":"Sumithira","family":"Vasu","sequence":"additional","affiliation":[{"name":"2Division of Hematology, The Ohio State University, Columbus, OH"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"234","published-online":{"date-parts":[[2026,7,17]]},"reference":[{"issue":"2","key":"2026072809371290500_bib1","doi-asserted-by":"crossref","first-page":"1159","DOI":"10.3390\/ijms24021159","article-title":"Transplant-associated thrombotic microangiopathy in the context of allogenic hematopoietic stem cell transplantation: where we stand","volume":"24","author":"Lazana","year":"2023","journal-title":"Int J Mol Sci"},{"issue":"5","key":"2026072809371290500_bib2","doi-asserted-by":"crossref","first-page":"638","DOI":"10.1097\/01.tp.0000230373.82376.46","article-title":"Risk factors and severe outcome in thrombotic microangiopathy after allogeneic hematopoietic stem cell transplantation","volume":"82","author":"Uderzo","year":"2006","journal-title":"Transplantation"},{"issue":"5","key":"2026072809371290500_bib3","doi-asserted-by":"crossref","first-page":"406","DOI":"10.1177\/08850666231200193","article-title":"Thrombotic microangiopathy after hematopoietic stem cell and solid organ transplantation: a review for intensive care physicians","volume":"39","author":"Nusrat","year":"2024","journal-title":"J Intensive Care Med"},{"issue":"7","key":"2026072809371290500_bib4","first-page":"392.e1","article-title":"Transplantation-associated thrombotic microangiopathy risk stratification: is there a window of opportunity to improve outcomes?","volume":"28","author":"Jodele","year":"2022","journal-title":"Transpl Cell Ther"},{"key":"2026072809371290500_bib5","doi-asserted-by":"crossref","first-page":"133","DOI":"10.3389\/fped.2019.00133","article-title":"Transplant-associated thrombotic microangiopathy in pediatric hematopoietic cell transplant recipients: a practical approach to diagnosis and management","volume":"7","author":"Dvorak","year":"2019","journal-title":"Front Pediatr"},{"issue":"3","key":"2026072809371290500_bib6","first-page":"151","article-title":"Harmonizing definitions for diagnostic criteria and prognostic assessment of transplantation-associated thrombotic microangiopathy: a report on behalf of the European Society for Blood and Marrow Transplantation, American Society for Transplantation and Cellular Therapy, Asia-Pacific Blood and Marrow Transplantation Group, and Center for International Blood and Marrow Transplant Research","volume":"29","author":"Schoettler","year":"2023","journal-title":"Transpl Cell Ther"},{"issue":"5","key":"2026072809371290500_bib7","doi-asserted-by":"crossref","first-page":"638","DOI":"10.1182\/blood.2025028390","article-title":"High incidence of severe TA-TMA increases mortality in adult allogeneic transplant recipients: a prospective MIDAS consortium study","volume":"146","author":"Vasu","year":"2025","journal-title":"Blood"},{"issue":"6","key":"2026072809371290500_bib8","doi-asserted-by":"crossref","first-page":"1171","DOI":"10.1111\/bjh.16457","article-title":"Incidence, risk factors for and outcomes of transplant-associated thrombotic microangiopathy","volume":"189","author":"Epperla","year":"2020","journal-title":"Br J Haematol"},{"issue":"4","key":"2026072809371290500_bib9","doi-asserted-by":"crossref","first-page":"540","DOI":"10.1038\/s41409-018-0293-3","article-title":"High mortality in hematopoietic stem cell transplant-associated thrombotic microangiopathy with and without concomitant acute graft-versus-host disease","volume":"54","author":"Kraft","year":"2019","journal-title":"Bone Marrow Transpl"},{"issue":"9","key":"2026072809371290500_bib10","doi-asserted-by":"crossref","first-page":"e13371","DOI":"10.1111\/ctr.13371","article-title":"Transplant-associated thrombotic microangiopathy: Incidence, prognostic factors, morbidity, and mortality in allogeneic hematopoietic cell transplantation","volume":"32","author":"Gavriilaki","year":"2018","journal-title":"Clin Transpl"},{"issue":"10","key":"2026072809371290500_bib11","doi-asserted-by":"crossref","first-page":"1399","DOI":"10.1038\/bmt.2017.119","article-title":"Transplant-associated thrombotic microangiopathy is an endothelial complication associated with refractoriness of acute GvHD","volume":"52","author":"Zeisbrich","year":"2017","journal-title":"Bone Marrow Transpl"},{"issue":"4","key":"2026072809371290500_bib12","doi-asserted-by":"crossref","first-page":"1342","DOI":"10.1182\/bloodadvances.2021004933","article-title":"BK virus hemorrhagic cystitis and age are risk factors for transplant-associated thrombotic microangiopathy in adults","volume":"6","author":"Vasu","year":"2022","journal-title":"Blood Adv"},{"issue":"25","key":"2026072809371290500_bib13","doi-asserted-by":"crossref","first-page":"2338","DOI":"10.1056\/NEJMoa2215943","article-title":"Post-transplantation cyclophosphamide-based graft-versus-host disease prophylaxis","volume":"388","author":"Bola\u00f1os-Meade","year":"2023","journal-title":"N Engl J Med Overseas Ed"},{"issue":"3","key":"2026072809371290500_bib14","doi-asserted-by":"crossref","first-page":"243","DOI":"10.1056\/NEJMoa2503189","article-title":"Graft-versus-host disease prophylaxis with cyclophosphamide and cyclosporin","volume":"393","author":"Curtis","year":"2025","journal-title":"New Engl J Med"},{"issue":"12","key":"2026072809371290500_bib15","doi-asserted-by":"crossref","first-page":"2306","DOI":"10.1016\/j.bbmt.2020.09.018","article-title":"Thrombotic microangiopathy after post-transplantation cyclophosphamide-based graft-versus-host disease prophylaxis","volume":"26","author":"Imus","year":"2020","journal-title":"Biol Blood Marrow Transplant"},{"issue":"3","key":"2026072809371290500_bib16","doi-asserted-by":"crossref","first-page":"e846","DOI":"10.1097\/HS9.0000000000000846","article-title":"Prediction of nonrelapse mortality in patients with acute myeloid leukemia and acute lymphoblastic leukemia receiving allogeneic stem cell transplantation with posttransplantation cyclophosphamide-based graft versus host disease prophylaxis","volume":"7","author":"Hermans","year":"2023","journal-title":"Hemasphere"},{"issue":"3","key":"2026072809371290500_bib17","doi-asserted-by":"crossref","first-page":"100020","DOI":"10.1016\/j.bvth.2024.100020","article-title":"Vascular biomarkers reveal a unique toxicity profile of posttransplant cyclophosphamide: secondary analysis of BMT CTN 0402 and 1202","volume":"1","author":"Newell","year":"2024","journal-title":"Blood Vessel Thromb Hemost"},{"issue":"1","key":"2026072809371290500_bib18","first-page":"16.e1","article-title":"Surrogates of endothelial injury predict survival after post-transplant cyclophosphamide","volume":"31","author":"Baranwal","year":"2025","journal-title":"Transpl Cell Ther"},{"issue":"4","key":"2026072809371290500_bib19","doi-asserted-by":"crossref","first-page":"1495","DOI":"10.1182\/blood-2004-11-4557","article-title":"Prospective evaluation of 2 acute graft-versus-host (GVHD) grading systems: a joint Societe Francaise de Greffe de Moelle et Therapie Cellulaire (SFGM-TC), Dana Farber Cancer Institute (DFCI), and International Bone Marrow Transplant Registry (IBMTR) prospective study","volume":"106","author":"Cahn","year":"2005","journal-title":"Blood"},{"issue":"10","key":"2026072809371290500_bib20","doi-asserted-by":"crossref","first-page":"1259","DOI":"10.1182\/blood-2017-05-782870","article-title":"Circulating dsDNA, endothelial injury, and complement activation in thrombotic microangiopathy and GVHD","volume":"130","author":"Gloude","year":"2017","journal-title":"Blood"},{"issue":"19","key":"2026072809371290500_bib21","doi-asserted-by":"crossref","first-page":"1737","DOI":"10.1056\/NEJMoa2102953","article-title":"New creatinine- and cystatin C\u2013based equations to estimate GFR without race","volume":"385","author":"Inker","year":"2021","journal-title":"N Engl J Med Overseas Ed"},{"issue":"2","key":"2026072809371290500_bib22","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1111\/j.2517-6161.1972.tb00899.x","article-title":"Regression models and life-tables","volume":"34","author":"Cox","year":"1972","journal-title":"J R Stat Soc Ser B Stat Methodol"},{"issue":"446","key":"2026072809371290500_bib23","doi-asserted-by":"crossref","first-page":"496","DOI":"10.1080\/01621459.1999.10474144","article-title":"A proportional hazards model for the subdistribution of a competing risk","volume":"94","author":"Fine","year":"1999","journal-title":"J Am Stat Assoc"},{"issue":"2","key":"2026072809371290500_bib24","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1177\/0049124104268644","article-title":"Multimodel inference","volume":"33","author":"Burnham","year":"2004","journal-title":"Sociol Methods Res"},{"key":"2026072809371290500_bib25","doi-asserted-by":"publisher","DOI":"10.1097\/JS9.0000000000004076","article-title":"Accelerated biological aging and postoperative acute kidney injury in surgical patients: a retrospective multicentre cohort analysis of 94,006 cases","author":"Yin","year":"19  2025","journal-title":"Int J Surg"},{"key":"2026072809371290500_bib26","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1016\/j.biochi.2025.10.008","article-title":"Premature aging in chronic kidney disease: decoding senescence biomarkers and therapeutic opportunities","volume":"240","author":"CEHVPF","year":"2026","journal-title":"Biochimie"},{"issue":"41","key":"2026072809371290500_bib27","doi-asserted-by":"crossref","first-page":"e45166","DOI":"10.1097\/MD.0000000000045166","article-title":"Accelerated biological aging and homeostatic dysregulation in diabetic kidney disease: evidence from NHANES and Mendelian randomization","volume":"104","author":"Wang","year":"2025","journal-title":"Medicine"},{"issue":"3","key":"2026072809371290500_bib28","doi-asserted-by":"crossref","first-page":"e195","DOI":"10.1016\/j.landig.2025.01.006","article-title":"Proteomic organ-specific ageing signatures and 20-year risk of age-related diseases: the Whitehall II observational cohort study","volume":"7","author":"Kivim\u00e4ki","year":"2025","journal-title":"Lancet Digit Health"},{"key":"2026072809371290500_bib29","doi-asserted-by":"publisher","DOI":"10.1101\/2025.09.07.25335188","article-title":"Eight decades of follow-up link life course exposures to proteomic organ ageing and longevity","author":"Groves","year":"8  2025","journal-title":"medRxiv"},{"issue":"1","key":"2026072809371290500_bib30","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1038\/s41392-023-01502-8","article-title":"Inflammation and aging: signaling pathways and intervention therapies","volume":"8","author":"Li","year":"2023","journal-title":"Signal Transduct Target Ther"},{"issue":"4","key":"2026072809371290500_bib31","doi-asserted-by":"crossref","first-page":"227","DOI":"10.3390\/toxins12040227","article-title":"Inflammation and premature ageing in chronic kidney disease","volume":"12","author":"Ebert","year":"2020","journal-title":"Toxins (Basel)"},{"issue":"8","key":"2026072809371290500_bib32","doi-asserted-by":"crossref","first-page":"1273","DOI":"10.1016\/j.stem.2022.06.012","article-title":"Inflammatory exposure drives long-lived impairment of hematopoietic stem cell self-renewal activity and accelerated aging","volume":"29","author":"Bogeska","year":"2022","journal-title":"Cell Stem Cell"},{"issue":"12","key":"2026072809371290500_bib33","doi-asserted-by":"crossref","first-page":"1189","DOI":"10.1056\/NEJMc1700185","article-title":"ST2 and endothelial injury as a link between GVHD and microangiopathy","volume":"376","author":"Rotz","year":"2017","journal-title":"N Engl J Med Overseas Ed"},{"issue":"6","key":"2026072809371290500_bib34","doi-asserted-by":"crossref","first-page":"529","DOI":"10.1056\/NEJMoa1213299","article-title":"ST2 as a marker for risk of therapy-resistant graft-versus-host disease and death","volume":"369","author":"Vander Lugt","year":"2013","journal-title":"N Engl J Med Overseas Ed"},{"issue":"suppl 3","key":"2026072809371290500_bib35","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1002\/ajh.27594","article-title":"Prediction and prognostication of acute graft-versus-host disease by MAGIC biomarkers","volume":"100","author":"Levine","year":"2025","journal-title":"Am J Hematol"},{"issue":"S2","key":"2026072809371290500_bib36","doi-asserted-by":"crossref","first-page":"e100391","DOI":"10.1002\/alz70856_100391","article-title":"Serum placental growth factor as a biomarker of cerebrovascular changes in Alzheimer\u2019s disease","volume":"21","author":"Dallaire-Th\u00e9roux","year":"2025","journal-title":"Alzheimer's Demen"},{"issue":"8","key":"2026072809371290500_bib37","doi-asserted-by":"crossref","DOI":"10.1101\/cshperspect.a011056","article-title":"PlGF: a multitasking cytokine with disease-restricted activity","volume":"2","author":"Dewerchin","year":"2012","journal-title":"Cold Spring Harb Perspect Med"},{"issue":"7","key":"2026072809371290500_bib38","doi-asserted-by":"crossref","first-page":"1823","DOI":"10.1111\/jth.15339","article-title":"Placental growth factor level in plasma predicts COVID-19 severity and in-hospital mortality","volume":"19","author":"Smadja","year":"2021","journal-title":"J Thromb Haemost"},{"issue":"10","key":"2026072809371290500_bib39","doi-asserted-by":"crossref","first-page":"1348","DOI":"10.1038\/s41590-019-0456-4","article-title":"Placental growth factor regulates the generation of TH17 cells to link angiogenesis with autoimmunity","volume":"20","author":"Yoo","year":"2019","journal-title":"Nat Immunol"},{"key":"2026072809371290500_bib40","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1016\/j.placenta.2025.05.023","article-title":"Placental growth factor enhances inflammatory toll-like receptor responses in syncytiotrophoblasts","volume":"168","author":"Newell","year":"2025","journal-title":"Placenta"},{"issue":"6","key":"2026072809371290500_bib41","doi-asserted-by":"crossref","first-page":"1029","DOI":"10.1016\/j.bbmt.2015.02.018","article-title":"Circulating angiogenic factors associated with response and survival in patients with acute graft-versus-host disease: results from Blood and Marrow Transplant Clinical Trials Network 0302 and 0802","volume":"21","author":"Holtan","year":"2015","journal-title":"Biol Blood Marrow Transpl"},{"issue":"18-20","key":"2026072809371290500_bib42","doi-asserted-by":"crossref","first-page":"1615","DOI":"10.1080\/17435889.2024.2368449","article-title":"Therapeutic effect of E-Lip-siRNA-sFlt1 on pre-eclampsia: targeted gene silencing and improved pregnancy outcomes","volume":"19","author":"Dong","year":"2024","journal-title":"Nanomedicine"},{"issue":"9","key":"2026072809371290500_bib43","doi-asserted-by":"crossref","first-page":"1300","DOI":"10.1038\/bmt.2017.89","article-title":"Low EGF in myeloablative allotransplantation: association with severe acute GvHD in BMT CTN 0402","volume":"52","author":"Holtan","year":"2017","journal-title":"Bone Marrow Transpl"},{"issue":"20","key":"2026072809371290500_bib44","doi-asserted-by":"crossref","first-page":"1632","DOI":"10.1182\/bloodadvances.2017008250","article-title":"In vitro evidence of complement activation in transplantation-associated thrombotic microangiopathy","volume":"1","author":"Rotz","year":"2017","journal-title":"Blood Adv"},{"issue":"20","key":"2026072809371290500_bib45","doi-asserted-by":"crossref","first-page":"e70906","DOI":"10.1111\/jcmm.70906","article-title":"Exploring the value of sC5b-9 in the diagnosis of haematopoietic stem cell transplant-associated thrombotic microangiopathy in children","volume":"29","author":"Luo","year":"2025","journal-title":"J Cell Mol Med"},{"key":"2026072809371290500_bib46","doi-asserted-by":"crossref","first-page":"1399696","DOI":"10.3389\/fonc.2024.1399696","article-title":"Transplant-associated thrombotic microangiopathy in pediatrics: incidence, risk factors, therapeutic options, and outcome based on data from a single center","volume":"14","author":"Kafa","year":"2024","journal-title":"Front Oncol"},{"issue":"2","key":"2026072809371290500_bib47","first-page":"S136","article-title":"Eculizumab treatment outcomes in patients with allogeneic hematopoietic cell transplant (alloHCT)-associated thrombotic microangiopathy (ta-tma): a retrospective single-center experience","volume":"30","author":"Samara","year":"2024","journal-title":"Transpl Cell Ther"},{"key":"2026072809371290500_bib48","doi-asserted-by":"crossref","first-page":"564647","DOI":"10.3389\/fimmu.2020.564647","article-title":"Efficacy and safety of eculizumab in the treatment of transplant-associated thrombotic microangiopathy: a systematic review and meta-analysis","volume":"11","author":"Zhang","year":"2020","journal-title":"Front Immunol"},{"issue":"5","key":"2026072809371290500_bib49","doi-asserted-by":"crossref","first-page":"830","DOI":"10.1002\/ajh.27651","article-title":"Clinical outcomes and treatment strategies of adult transplant-associated thrombotic microangiopathy: external validation of harmonizing definitions and high-risk criteria","volume":"100","author":"Acosta-Medina","year":"2025","journal-title":"Am J Hematol"},{"issue":"13","key":"2026072809371290500_bib50","first-page":"1049","article-title":"Complement blockade for TA-TMA: lessons learned from large pediatric cohort treated with eculizumab","volume":"135","author":"Jodele","year":"2020","journal-title":"Blood"},{"issue":"4","key":"2026072809371290500_bib51","first-page":"503.e1","article-title":"Outcomes of terminal complement blockade in adults with high-risk transplant-associated thrombotic microangiopathy: a comparative analysis","volume":"32","author":"Alhomoud","year":"2025","journal-title":"Transpl Cell Ther"},{"issue":"3","key":"2026072809371290500_bib52","doi-asserted-by":"crossref","first-page":"553","DOI":"10.1038\/s41409-019-0703-1","article-title":"EASIX and mortality after allogeneic stem cell transplantation","volume":"55","author":"Luft","year":"2020","journal-title":"Bone Marrow Transpl"},{"issue":"1","key":"2026072809371290500_bib53","doi-asserted-by":"crossref","first-page":"e007635","DOI":"10.1136\/jitc-2023-007635","article-title":"Endothelial activation and stress index (EASIX) to predict mortality after allogeneic stem cell transplantation: a prospective study","volume":"12","author":"Penack","year":"2024","journal-title":"J Immunother Cancer"},{"issue":"1","key":"2026072809371290500_bib54","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1016\/j.bbmt.2012.09.018","article-title":"Endothelial vulnerability and endothelial damage are associated with risk of graft-versus-host disease and response to steroid treatment","volume":"19","author":"Dietrich","year":"2013","journal-title":"Biol Blood Marrow Transpl"}],"container-title":["Blood Advances"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/ashpublications.org\/bloodadvances\/article-pdf\/10\/14\/5076\/2534340\/blooda_adv-2026-019747-main.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/ashpublications.org\/bloodadvances\/article-pdf\/10\/14\/5076\/2534340\/blooda_adv-2026-019747-main.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,28]],"date-time":"2026-07-28T13:37:24Z","timestamp":1785245844000},"score":1,"resource":{"primary":{"URL":"https:\/\/ashpublications.org\/bloodadvances\/article\/10\/14\/5076\/568866\/TA-TMA-and-GVHD-are-distinct-consequences-of"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7,17]]},"references-count":54,"journal-issue":{"issue":"14","published-print":{"date-parts":[[2026,7,28]]}},"URL":"https:\/\/doi.org\/10.1182\/bloodadvances.2026019747","relation":{},"ISSN":["2473-9529","2473-9537"],"issn-type":[{"value":"2473-9529","type":"print"},{"value":"2473-9537","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2026,7,28]]},"published":{"date-parts":[[2026,7,17]]}}}